As of Apr 28
| -0.13 / -1.39%|
The 16 analysts offering 12-month price forecasts for Valeant Pharmaceuticals have a median target of 15.50, with a high estimate of 45.00 and a low estimate of 8.00. The median estimate represents a +67.57% increase from the last price of 9.25.
The current consensus among 21 polled investment analysts is to Hold stock in Valeant Pharmaceuticals. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.